SCHEMBL30611682

SCHEMBL30611682

O=C(NS(=O)(=O)c1cccc(N2CCN3C(=O)CCC3C2)n1)C1CC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 4/20 0.34
▸ CNR1 P21554 2/20 0.34
▸ CNR2 P34972 2/20 0.34
▸ CTSC P53634 1/20 0.34
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ STS P08842 1/20 0.33
▸ NAMPT P43490 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ SOS1 Q07889 2/20 0.33
▸ ACACB O00763 1/20 0.33
▸ POLB P06746 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ CA12 O43570 2/20 0.32
▸ CA1 P00915 2/20 0.32
▸ CA2 P00918 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22116366 0.81 ABL1 (0.43) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL22116414 0.81 ABL1 (0.43) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL30611688 0.81 ABL1 (0.43) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL30611680 0.81 ABL1 (0.43) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL22116413 0.79 HPGD (0.39) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL22116343 0.77 ACACB (0.46) ACACB
SCHEMBL22116346 0.77 KIF18A (0.50) —
SCHEMBL30611713 0.76 PTGER4 (0.42) CYP3A4CYP2C19POLB
SCHEMBL22116293 0.75 JAK2 (0.39) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL22116332 0.74 HSD11B1 (0.44) STSHPGDACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3897832-B1 N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE NOVARTIS AG (CH) 2023-10-11 — — EP claimed
Send feedback